Thrombomodulin -33G/A and Ala455Val polymorphisms are associated with the risk of coronary artery disease: a meta-analysis including 12 584 patients.
Thrombomodulin (TM) -33G/A and Ala455Val polymorphisms have been indicated to be correlated with the risk of coronary artery disease (CAD), but study results are still inclusive. Thus, a meta-analysis was carried out. Databases including PubMed, Embase, CNKI, and Web of Science (ISI) were searched. Data were extracted and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Thirteen case-control studies on the relationship between TM -33G/A and Ala455Val polymorphisms and the risk of CAD were included in this meta-analysis. The association between the TM -33G/A polymorphism and the risk of CAD was significant (OR=1.65; 95% CI, 1.35-2.02; P<0.01; I(2)=15%). This result remained statistically significant when the adjusted ORs were combined (OR=1.50; 95% CI, 1.23-1.84; P<0.01; I(2)=0%). The association between the TM Ala455Val polymorphism and the risk of CAD was also significant (OR=1.14; 95% CI, 1.05-1.24; P<0.01; I(2)=0%). This result remained statistically significant when the adjusted ORs were combined (OR=1.57; 95% CI, 1.05-2.34; P=0.03; I(2)=32%). This meta-analysis suggested that TM -33G/A and Ala455Val polymorphisms were risk factors for CAD.